Gilead Sciences (GILD) Surges As Bristol-Myers' (BMY) Hep C Drug Has Major Setback
Go back to Gilead Sciences (GILD) Surges As Bristol-Myers' (BMY) Hep C Drug Has Major Setback| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 67.88 +1.83 (2.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.05 | 52 Week High | $77.12 | |||
| Open | $66.80 | 52 Week Low | $49.03 | |||
| Day High | $68.64 | P/E | 44.08 | |||
| Day Low | $66.61 | EPS | $1.54 | |||
| Volume | 5,040,808 | |||||
| Gilead Sciences (NASDAQ: GILD) | Delayed: 147.65 +4.21 (2.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.44 | 52 Week High | $108.63 | |||
| Open | $145.10 | 52 Week Low | $71.39 | |||
| Day High | $148.97 | P/E | 81.57 | |||
| Day Low | $144.30 | EPS | $1.81 | |||
| Volume | 1,804,374 | |||||
